Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

被引：0
|
作者：
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology
来源：
Breast Cancer Research and Treatment | 2023年 / 199卷
关键词：
Pegylated liposomal doxorubicin; Metastatic breast cancer; HER2-negative; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 79
页数：12
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
    Jiang, Hanfang
    Li, Huiping
    Song, Guohong
    Di, Lijun
    Shao, Bin
    Yan, Ying
    Liu, Xiaoran
    Chen, Yifei
    Zhang, Ruyan
    Ran, Ran
    Liu, Yaxin
    Gui, Xinyu
    Wang, Nan
    Wang, Huan
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 67 - 79
  • [2] A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer.
    Hu, Nanlin
    Yuan, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients
    Fabi, A
    Ferretti, G
    Papaldo, P
    Salesi, N
    Ciccarese, M
    Lorusso, V
    Carlini, P
    Carpino, A
    Mottolese, M
    Cianciulli, AM
    Giannarelli, D
    Sperduti, I
    Felici, A
    Cognetti, F
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 615 - 623
  • [4] Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
    Jehn, Christian F.
    Hemmati, Philipp
    Lehenbauer-Dehm, Silvia
    Kuemmel, Sherko
    Flath, Bernd
    Schmid, Peter
    CLINICAL BREAST CANCER, 2016, 16 (06) : 514 - 519
  • [5] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
    Alessandra Fabi
    Gianluigi Ferretti
    Paola Papaldo
    Nello Salesi
    Mariangela Ciccarese
    Vito Lorusso
    Paolo Carlini
    Armando Carpino
    Marcella Mottolese
    Anna Maria Cianciulli
    Diana Giannarelli
    Isabella Sperduti
    Alessandra Felici
    Francesco Cognetti
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 615 - 623
  • [6] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study
    Yin, Y.
    Wu, X.
    Huang, X.
    Li, W.
    Hua, Y.
    Liang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S648 - S649
  • [7] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study.
    Yin, Yongmei
    Wu, Xinyu
    Hua, Yijia
    Sun, Chunxiao
    Liang, Yan
    Yang, Fan
    Huang, Xiang
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer
    Chow, Louis Wing-Cheong
    Yip, Adrian Yun-San
    Lang, Brian Hung-Hin
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (02): : 133 - 138
  • [9] Anlotinib in pre-treated metastatic HER2-negative breast cancer: A phase II, single-arm clinical study
    Hu, Nanlin
    Luo, Yang
    Wang, Jiayu
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Xu, Binghe
    Yuan, Peng
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
    Liu, Jiaxuan
    He, Maiyue
    Jiang, Mingxia
    Zhou, Shihan
    Zhang, Mengqi
    Li, Yiqun
    Chen, Shanshan
    Cai, Ruigang
    Mo, Hongnan
    Lan, Bo
    Ma, Fei
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
12345